[
  {
    "sentence": "Recommended immunotherapies for MCC\nCompared with first-line chemotherapy, responses to ICIs have been found to be more durable and offer prolonged survival for a subset of patients with advanced MCC.52 Two ICIs have received FDA approval for the treatment of MCC at the time of guideline publication: avelumab and pembrolizumab.8 A summary of the FDA-approved ICIs (at the time of guideline publication) for MCC, CSCC, and BCC is depicted in figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Approved anti-PD-1 agents for CSCC\nTwo anti-PD-1 ICIs have been approved by the FDA for the treatment of CSCC: pembrolizumab and cemiplimab (figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Other treatment modalities include radiation therapy, cryotherapy (for superficial tumors), electrodessication and curettage (for low-risk tumors), topical imiquimod (for superficial tumors), and topical 5-fluorouracil (for superficial tumors).133 For patients with advanced BCC, where surgery or radiation are not options, systemic hedgehog pathway inhibitors (HHIs), including vismodegib and sonidegib, have demonstrated efficacy.134 The approval by the FDA of cemiplimab for the treatment of BCC (figure 1) in February 2021 has now provided a systemic therapy option for patients who are not candidates for or are intolerant to HHIs, or whose cancer is refractory to HHIs, surgery, or radiation.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Recommended immunotherapies for MCC\nCompared with first-line chemotherapy, responses to ICIs have been found to be more durable and offer prolonged survival for a subset of patients with advanced MCC.52 Two ICIs have received FDA approval for the treatment of MCC at the time of guideline publication: avelumab and pembrolizumab.8 A summary of the FDA-approved ICIs (at the time of guideline publication) for MCC, CSCC, and BCC is depicted in figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Approved anti-PD-1 agents for CSCC\nTwo anti-PD-1 ICIs have been approved by the FDA for the treatment of CSCC: pembrolizumab and cemiplimab (figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Other treatment modalities include radiation therapy, cryotherapy (for superficial tumors), electrodessication and curettage (for low-risk tumors), topical imiquimod (for superficial tumors), and topical 5-fluorouracil (for superficial tumors).133 For patients with advanced BCC, where surgery or radiation are not options, systemic hedgehog pathway inhibitors (HHIs), including vismodegib and sonidegib, have demonstrated efficacy.134 The approval by the FDA of cemiplimab for the treatment of BCC (figure 1) in February 2021 has now provided a systemic therapy option for patients who are not candidates for or are intolerant to HHIs, or whose cancer is refractory to HHIs, surgery, or radiation.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Recommended immunotherapies for MCC\nCompared with first-line chemotherapy, responses to ICIs have been found to be more durable and offer prolonged survival for a subset of patients with advanced MCC.52 Two ICIs have received FDA approval for the treatment of MCC at the time of guideline publication: avelumab and pembrolizumab.8 A summary of the FDA-approved ICIs (at the time of guideline publication) for MCC, CSCC, and BCC is depicted in figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Approved anti-PD-1 agents for CSCC\nTwo anti-PD-1 ICIs have been approved by the FDA for the treatment of CSCC: pembrolizumab and cemiplimab (figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Other treatment modalities include radiation therapy, cryotherapy (for superficial tumors), electrodessication and curettage (for low-risk tumors), topical imiquimod (for superficial tumors), and topical 5-fluorouracil (for superficial tumors).133 For patients with advanced BCC, where surgery or radiation are not options, systemic hedgehog pathway inhibitors (HHIs), including vismodegib and sonidegib, have demonstrated efficacy.134 The approval by the FDA of cemiplimab for the treatment of BCC (figure 1) in February 2021 has now provided a systemic therapy option for patients who are not candidates for or are intolerant to HHIs, or whose cancer is refractory to HHIs, surgery, or radiation.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Recommended immunotherapies for MCC\nCompared with first-line chemotherapy, responses to ICIs have been found to be more durable and offer prolonged survival for a subset of patients with advanced MCC.52 Two ICIs have received FDA approval for the treatment of MCC at the time of guideline publication: avelumab and pembrolizumab.8 A summary of the FDA-approved ICIs (at the time of guideline publication) for MCC, CSCC, and BCC is depicted in figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Approved anti-PD-1 agents for CSCC\nTwo anti-PD-1 ICIs have been approved by the FDA for the treatment of CSCC: pembrolizumab and cemiplimab (figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Other treatment modalities include radiation therapy, cryotherapy (for superficial tumors), electrodessication and curettage (for low-risk tumors), topical imiquimod (for superficial tumors), and topical 5-fluorouracil (for superficial tumors).133 For patients with advanced BCC, where surgery or radiation are not options, systemic hedgehog pathway inhibitors (HHIs), including vismodegib and sonidegib, have demonstrated efficacy.134 The approval by the FDA of cemiplimab for the treatment of BCC (figure 1) in February 2021 has now provided a systemic therapy option for patients who are not candidates for or are intolerant to HHIs, or whose cancer is refractory to HHIs, surgery, or radiation.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Recommended immunotherapies for MCC\nCompared with first-line chemotherapy, responses to ICIs have been found to be more durable and offer prolonged survival for a subset of patients with advanced MCC.52 Two ICIs have received FDA approval for the treatment of MCC at the time of guideline publication: avelumab and pembrolizumab.8 A summary of the FDA-approved ICIs (at the time of guideline publication) for MCC, CSCC, and BCC is depicted in figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Approved anti-PD-1 agents for CSCC\nTwo anti-PD-1 ICIs have been approved by the FDA for the treatment of CSCC: pembrolizumab and cemiplimab (figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Other treatment modalities include radiation therapy, cryotherapy (for superficial tumors), electrodessication and curettage (for low-risk tumors), topical imiquimod (for superficial tumors), and topical 5-fluorouracil (for superficial tumors).133 For patients with advanced BCC, where surgery or radiation are not options, systemic hedgehog pathway inhibitors (HHIs), including vismodegib and sonidegib, have demonstrated efficacy.134 The approval by the FDA of cemiplimab for the treatment of BCC (figure 1) in February 2021 has now provided a systemic therapy option for patients who are not candidates for or are intolerant to HHIs, or whose cancer is refractory to HHIs, surgery, or radiation.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Recommended immunotherapies for MCC\nCompared with first-line chemotherapy, responses to ICIs have been found to be more durable and offer prolonged survival for a subset of patients with advanced MCC.52 Two ICIs have received FDA approval for the treatment of MCC at the time of guideline publication: avelumab and pembrolizumab.8 A summary of the FDA-approved ICIs (at the time of guideline publication) for MCC, CSCC, and BCC is depicted in figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Approved anti-PD-1 agents for CSCC\nTwo anti-PD-1 ICIs have been approved by the FDA for the treatment of CSCC: pembrolizumab and cemiplimab (figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Other treatment modalities include radiation therapy, cryotherapy (for superficial tumors), electrodessication and curettage (for low-risk tumors), topical imiquimod (for superficial tumors), and topical 5-fluorouracil (for superficial tumors).133 For patients with advanced BCC, where surgery or radiation are not options, systemic hedgehog pathway inhibitors (HHIs), including vismodegib and sonidegib, have demonstrated efficacy.134 The approval by the FDA of cemiplimab for the treatment of BCC (figure 1) in February 2021 has now provided a systemic therapy option for patients who are not candidates for or are intolerant to HHIs, or whose cancer is refractory to HHIs, surgery, or radiation.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Recommended immunotherapies for MCC\nCompared with first-line chemotherapy, responses to ICIs have been found to be more durable and offer prolonged survival for a subset of patients with advanced MCC.52 Two ICIs have received FDA approval for the treatment of MCC at the time of guideline publication: avelumab and pembrolizumab.8 A summary of the FDA-approved ICIs (at the time of guideline publication) for MCC, CSCC, and BCC is depicted in figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Approved anti-PD-1 agents for CSCC\nTwo anti-PD-1 ICIs have been approved by the FDA for the treatment of CSCC: pembrolizumab and cemiplimab (figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Other treatment modalities include radiation therapy, cryotherapy (for superficial tumors), electrodessication and curettage (for low-risk tumors), topical imiquimod (for superficial tumors), and topical 5-fluorouracil (for superficial tumors).133 For patients with advanced BCC, where surgery or radiation are not options, systemic hedgehog pathway inhibitors (HHIs), including vismodegib and sonidegib, have demonstrated efficacy.134 The approval by the FDA of cemiplimab for the treatment of BCC (figure 1) in February 2021 has now provided a systemic therapy option for patients who are not candidates for or are intolerant to HHIs, or whose cancer is refractory to HHIs, surgery, or radiation.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Recommended immunotherapies for MCC\nCompared with first-line chemotherapy, responses to ICIs have been found to be more durable and offer prolonged survival for a subset of patients with advanced MCC.52 Two ICIs have received FDA approval for the treatment of MCC at the time of guideline publication: avelumab and pembrolizumab.8 A summary of the FDA-approved ICIs (at the time of guideline publication) for MCC, CSCC, and BCC is depicted in figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Approved anti-PD-1 agents for CSCC\nTwo anti-PD-1 ICIs have been approved by the FDA for the treatment of CSCC: pembrolizumab and cemiplimab (figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Other treatment modalities include radiation therapy, cryotherapy (for superficial tumors), electrodessication and curettage (for low-risk tumors), topical imiquimod (for superficial tumors), and topical 5-fluorouracil (for superficial tumors).133 For patients with advanced BCC, where surgery or radiation are not options, systemic hedgehog pathway inhibitors (HHIs), including vismodegib and sonidegib, have demonstrated efficacy.134 The approval by the FDA of cemiplimab for the treatment of BCC (figure 1) in February 2021 has now provided a systemic therapy option for patients who are not candidates for or are intolerant to HHIs, or whose cancer is refractory to HHIs, surgery, or radiation.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Recommended immunotherapies for MCC\nCompared with first-line chemotherapy, responses to ICIs have been found to be more durable and offer prolonged survival for a subset of patients with advanced MCC.52 Two ICIs have received FDA approval for the treatment of MCC at the time of guideline publication: avelumab and pembrolizumab.8 A summary of the FDA-approved ICIs (at the time of guideline publication) for MCC, CSCC, and BCC is depicted in figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Recommended immunotherapies for MCC\nCompared with first-line chemotherapy, responses to ICIs have been found to be more durable and offer prolonged survival for a subset of patients with advanced MCC.52 Two ICIs have received FDA approval for the treatment of MCC at the time of guideline publication: avelumab and pembrolizumab.8 A summary of the FDA-approved ICIs (at the time of guideline publication) for MCC, CSCC, and BCC is depicted in figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Compared with first-line chemotherapy, responses to ICIs have been found to be more durable and offer prolonged survival for a subset of patients with advanced MCC.52 Two ICIs have received FDA approval for the treatment of MCC at the time of guideline publication: avelumab and pembrolizumab.8 A summary of the FDA-approved ICIs (at the time of guideline publication) for MCC, CSCC, and BCC is depicted in figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Approved anti-PD-1 agents for CSCC\nTwo anti-PD-1 ICIs have been approved by the FDA for the treatment of CSCC: pembrolizumab and cemiplimab (figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Approved anti-PD-1 agents for CSCC\nTwo anti-PD-1 ICIs have been approved by the FDA for the treatment of CSCC: pembrolizumab and cemiplimab (figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Approved anti-PD-1 agents for CSCC\nTwo anti-PD-1 ICIs have been approved by the FDA for the treatment of CSCC: pembrolizumab and cemiplimab (figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Two anti-PD-1 ICIs have been approved by the FDA for the treatment of CSCC: pembrolizumab and cemiplimab (figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Other treatment modalities include radiation therapy, cryotherapy (for superficial tumors), electrodessication and curettage (for low-risk tumors), topical imiquimod (for superficial tumors), and topical 5-fluorouracil (for superficial tumors).133 For patients with advanced BCC, where surgery or radiation are not options, systemic hedgehog pathway inhibitors (HHIs), including vismodegib and sonidegib, have demonstrated efficacy.134 The approval by the FDA of cemiplimab for the treatment of BCC (figure 1) in February 2021 has now provided a systemic therapy option for patients who are not candidates for or are intolerant to HHIs, or whose cancer is refractory to HHIs, surgery, or radiation.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Other treatment modalities include radiation therapy, cryotherapy (for superficial tumors), electrodessication and curettage (for low-risk tumors), topical imiquimod (for superficial tumors), and topical 5-fluorouracil (for superficial tumors).133 For patients with advanced BCC, where surgery or radiation are not options, systemic hedgehog pathway inhibitors (HHIs), including vismodegib and sonidegib, have demonstrated efficacy.134 The approval by the FDA of cemiplimab for the treatment of BCC (figure 1) in February 2021 has now provided a systemic therapy option for patients who are not candidates for or are intolerant to HHIs, or whose cancer is refractory to HHIs, surgery, or radiation.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Other treatment modalities include radiation therapy, cryotherapy (for superficial tumors), electrodessication and curettage (for low-risk tumors), topical imiquimod (for superficial tumors), and topical 5-fluorouracil (for superficial tumors).133 For patients with advanced BCC, where surgery or radiation are not options, systemic hedgehog pathway inhibitors (HHIs), including vismodegib and sonidegib, have demonstrated efficacy.134 The approval by the FDA of cemiplimab for the treatment of BCC (figure 1) in February 2021 has now provided a systemic therapy option for patients who are not candidates for or are intolerant to HHIs, or whose cancer is refractory to HHIs, surgery, or radiation.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  }
]